Point72 Asset Management L.P. Sells 316,295 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Point72 Asset Management L.P. reduced its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 94.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,421 shares of the medical equipment provider's stock after selling 316,295 shares during the period. Point72 Asset Management L.P.'s holdings in Lantheus were worth $1,912,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LNTH. GAMMA Investing LLC increased its position in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 208 shares in the last quarter. Signaturefd LLC raised its stake in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after buying an additional 92 shares during the last quarter. Nkcfo LLC acquired a new stake in Lantheus during the 2nd quarter worth about $47,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after purchasing an additional 126 shares during the period. Finally, Kathleen S. Wright Associates Inc. acquired a new position in shares of Lantheus during the 3rd quarter valued at $51,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Trading Down 1.2 %

Shares of LNTH stock traded down $1.12 during mid-day trading on Tuesday, reaching $91.46. The stock had a trading volume of 315,448 shares, compared to its average volume of 1,012,238. The firm has a market capitalization of $6.36 billion, a PE ratio of 15.40 and a beta of 0.45. The stock's 50-day moving average price is $99.04 and its two-hundred day moving average price is $97.75. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89.

Wall Street Analyst Weigh In

LNTH has been the subject of several analyst reports. Redburn Atlantic started coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective for the company. Truist Financial restated a "buy" rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com downgraded shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Finally, JMP Securities lowered their price objective on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Lantheus presently has a consensus rating of "Moderate Buy" and a consensus target price of $130.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.